Biocon's anti-CD6 mAb meets primary endpoint in Indian psoriasis study
This article was originally published in Scrip
Executive Summary
Biocon has reported that itolizumab, its investigational anti-CD6 monoclonal antibody, has met its primary endpoint in a late-stage study to treat psoriasis in India.